Furthermore, both leukemic B cells and CLL T cells are responsive to IL-17F-mediated signaling, specifically activating NFkB, whereas B and T cells from age-matched healthy controls are not. This evidence concerns the gene IL17F and B-cell chronic lymphocytic leukemia.